Furthermore, in at-risk individuals carrying causal genetic variants of ALS, the spatial and temporal specificity of TDP-REG could allow the therapeutics to be delivered at the pre-symptomatic stage, lying dormant until the very first stages of TDP-43 pathology are detected. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.